78 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
7:00am
,” “predictive,” “strategy,” "support," “will” and similar statements of a future or forward-looking nature. These statements are neither promises nor
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
,” “predictive,” “strategy,” "support," “will” and similar statements of a future or forward-looking nature. These statements are neither promises nor
S-3ASR
EX-1.2
ZNTL
Zentalis Pharmaceuticals Inc
29 Feb 24
Automatic shelf registration
5:14pm
that it shall be liable for any settlement of the nature contemplated by Section 9(a) effected without its written consent if (i) such settlement
S-3ASR
EX-4.3
ZNTL
Zentalis Pharmaceuticals Inc
29 Feb 24
Automatic shelf registration
5:14pm
making such certificate or opinion has read such covenant or condition;
(b) a brief statement as to the nature and scope of the examination
8-K
EX-99.2
gcs80kitk8437aq
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
efhu 2twlf
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
akflxch1
9 Aug 23
Regulation FD Disclosure
4:15pm
8-K
EX-1.1
m1e1xqxj8mq shi0t
15 Jun 23
Other Events
4:23pm
424B5
yyotu0wonmoadgapvr
15 Jun 23
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.2
qmyyzynt
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am